GOLPH3 promotes glioblastoma cell migration and invasion via the mTOR-YB1 pathway in vitro

Molecular Carcinogenesis

Volumn 54, Issue 11, 2015, Pages 1252-1263

  Zhang, Xu ^a   Ding, Zhijun ^a   Mo, Jianbing ^a   Sang, Ben ^a   Shi, Qiong ^a   Hu, Jinxia ^a   Xie, Shao ^a   Zhan, Wenjian ^a   Lu, Dong ^a   Yang, Minglin ^a   Bian, Wenbin ^a   Zhou, Xiuping ^a   Yu, Rutong ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Glioma; GOLPH3; Invasion; Migration; MTOR; YB1

Indexed keywords

GOLGI PHOSPHOPROTEIN 3; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHOPROTEIN; SAPANISERTIB; UNCLASSIFIED DRUG; Y BOX BINDING PROTEIN 1; GOLPH3 PROTEIN, HUMAN; MEMBRANE PROTEIN; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; YBX1 PROTEIN, HUMAN;

ARTICLE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UPREGULATION; BRAIN TUMOR; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; GLIOBLASTOMA; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION;

BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MEMBRANE PROTEINS; NEOPLASM INVASIVENESS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; UP-REGULATION; Y-BOX-BINDING PROTEIN 1;

EID: 84945185696     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22197     Document Type: Article

References (37)

1. Huse JT, Holland EC. Targeting brain cancer: Advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 2010; 10:319-331.
2. Clarke J, Butowski N, Chang S. Recent advances in therapy for glioblastoma. Arch Neurol 2010; 67:279-283.
3. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359:492-507.
4. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-996.
5. Manji HK, Quiroz JA, Sporn J, et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 2003; 53:707-742.
6. Snyder CM, Mardones GA, Ladinsky MS, Howell KE. GMx33 associates with the trans-Golgi matrix in a dynamic manner and sorts within tubules exiting the Golgi. Mol Biol Cell 2006; 17:511-524.
7. Dippold HC, Ng MM, Farber-Katz SE, et al. GOLPH3 bridges phosphatidylinositol-4-phosphate and actomyosin to stretch and shape the Golgi to promote budding. Cell 2009; 139:337-351.
8. Wood CS, Schmitz KR, Bessman NJ, Setty TG, Ferguson KM, Burd CG. PtdIns4P recognition by Vps74/GOLPH3 links PtdIns 4-kinase signaling to retrograde Golgi trafficking. J Cell Biol 2009; 187:967-975.
9. Schmitz KR, Liu J, Li S, et al. Golgi localization of glycosyltransferases requires a Vps74p oligomer. Dev Cell 2008; 14:523-534.
10. Tu L, Tai WC, Chen L, Banfield DK. Signal-mediated dynamic retention of glycosyltransferases in the Golgi. Science 2008; 321:404-407.
11. Scott KL, Kabbarah O, Liang MC, et al. GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature 2009; 459:1085-1090.
12. Sabatini DM. mTOR and cancer: Insights into a complex relationship. Nat Rev Cancer 2006; 6:729-734.
13. Kunigou O, Nagao H, Kawabata N, et al. Role of GOLPH3 and GOLPH3L in the proliferation of human rhabdomyosarcoma. Oncol Rep 2011; 26:1337-1342.
14. Li XY, Liu W, Chen SF, Zhang LQ, Li XG, Wang LX. Expression of the Golgi phosphoprotein-3 gene in human gliomas: A pilot study. J Neurooncol 2011; 105:159-163.
15. Zhou X, Zhan W, Bian W, et al. GOLPH3 regulates the migration and invasion of glioma cells though RhoA. Biochem Biophys Res Commun 2013; 433:338-344.
16. Evdokimova VM, Ovchinnikov LP. Translational regulation by Y-box transcription factor: Involvement of the major mRNA-associated protein, p50. Int J Biochem Cell Biol 1999; 31:139-149.
17. Kohno K, Izumi H, Uchiumi T, Ashizuka M, Kuwano M. The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays 2003; 25:691-698.
18. Lyabin DN, Eliseeva IA, Ovchinnikov LP. YB-1 Synthesis is regulated by mTOR signaling pathway. PLoS ONE 2012; 7:1-11.
19. Stein U, Jürchott K, Walther W, Bergmann S, Schlag PM, Royer HD. Hyperthermia-induced nuclear translocation of transcription factor YB-1 leads to enhanced expression of multidrug resistance-related ABC transporters. J Biol Chem 2001; 276:28562-28569.
20. Ohga T, Koike K, Ono M, et al. Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res 1996; 56:4224-4228.
21. Bargou RC, Jürchott K, Wagener C, et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 1997; 3:447-450.
22. Kuwano M, Oda Y, Izumi H, et al. The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol Cancer Ther 2004; 3:1485-1492.
23. Knösel T, Emde A, Schlüns K, et al. Immunoprofiles of 11 biomarkers using tissue microarrays identify prognostic subgroups in colorectal cancer. Neoplasia 2005; 7:741-747.
24. To K, Fotovati A, Reipas KM, et al. Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. Cancer Res 2010; 70:2840-2851.
25. Bader AG, Vogt PK. Inhibition of protein synthesis by Y box-binding protein 1 blocks oncogenic cell transformation. Mol Cell Biol 2005; 25:2095-2106.
26. Evdokimova V, Tognon C, Ng T, et al. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell 2009; 15:402-415.
27. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006; 7:131-142.
28. Janz M, Harbeck N, Dettmar P, et al. Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer 2002; 97:278-282.
29. Bergmann S, Royer-Pokora B, Fietze E, et al. YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res 2005; 65:4078-4087.
30. Ng MM, Dippold HC, Buschman MD, Noakes CJ, Field SJ. GOLPH3L antagonizes GOLPH3 to determine Golgi morphology. Mol Biol Cell 2013; 24:796-808.
31. Fasolo A, Sessa C. Targeting mTOR pathways in human malignancies. Curr Pharm Des 2012; 18:2766-2777.
32. Hsieh AC, Liu Y, Edlind MP, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 2012; 485:55-61.
33. Brown EJ, Beal PA, Keith CT, Chen J, Shin TB, Schreiber SL. Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature 1995; 377:441-446.
34. Gingras AC, Kennedy SG, O'Leary MA, Sonenberg N, Hay N. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes 1998; 12:502-513.
35. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001; 15:807-826.
36. Ruvinsky I, Meyuhas O. Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem Sci 2006; 31:342-348.
37. Wedel S, Hudak L, Seibel JM, et al. Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells. Clin Exp Metastasis 2011; 28:479-491.